Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

BriaCell Therapeutics (BCTX) Stock Price & Analysis

336 Followers

BCTX Stock Chart & Stats

$3.59-$0.10(-2.71%)
At close: 4:00 PM EST
$3$3.5$4Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$3.56 - $3.75
52-Week Range
$2.60 - $13.09
Previous Close
$3.69
Volume
N/A
Average Volume (3M)
64.21K
Market Cap
$31.86M
Enterprise Value
$11.98M
Total Cash (Recent Filing)
$20.53M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
1.52
Next Earnings
Dec 10, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Very Low Leverage

The absence of meaningful debt reduces solvency pressure and avoids interest obligations while BriaCell funds clinical development. This gives management greater flexibility than a highly levered biotech, although it does not eliminate the need for future financing.

Positive Equity Base

A positive equity balance provides a financial base for ongoing research and clinical operations and indicates recapitalization or funding support has occurred. This improves resilience relative to prior negative-equity periods, despite subsequent erosion from continuing losses.

Focused Oncology Pipeline

BriaCell has a defined strategic focus in cancer immunotherapy, centered on a lead cell-based program and combination approaches intended to improve immune responses. Advancing a focused pipeline can concentrate scientific resources and create value if clinical development succeeds.

Bears Say

No Commercial Revenue

The absence of revenue means BriaCell currently lacks an operating income stream to fund research, trials, or corporate expenses. Until a candidate reaches commercialization, progress remains dependent on financing, partnerships, or other external capital sources.

Widening Net Losses

Widening losses indicate that operating expenses continue to outpace the company’s ability to generate income, increasing the capital required to advance the pipeline. Persistent deterioration can constrain development choices and weaken financial flexibility over multiple quarters.

Heavy Cash Burn

Sustained negative operating and free cash flow shows that ongoing activities consume substantial cash rather than replenish it. The magnitude of the burn raises dependence on capital raises or partnerships and makes funding continuity important to clinical execution.

BriaCell Therapeutics News

BCTX FAQ

What was BriaCell Therapeutics’s price range in the past 12 months?
BriaCell Therapeutics lowest stock price was $2.60 and its highest was $13.09 in the past 12 months.
What is BriaCell Therapeutics’s market cap?
BriaCell Therapeutics’s market cap is $31.86M.
When is BriaCell Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BriaCell Therapeutics’s earnings last quarter?
BriaCell Therapeutics released its earnings results on Oct 28, 2026. The company reported -$1.414 earnings per share for the quarter.
Is BriaCell Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does BriaCell Therapeutics pay dividends?
BriaCell Therapeutics does not currently pay dividends.
What is BriaCell Therapeutics’s EPS estimate?
BriaCell Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BriaCell Therapeutics have?
BriaCell Therapeutics has 8,732,381 shares outstanding.
What happened to BriaCell Therapeutics’s price movement after its last earnings report?
BriaCell Therapeutics reported an EPS of -$1.414 in its last earnings report. Following the earnings report the stock price went down -5.429%.
Which hedge fund is a major shareholder of BriaCell Therapeutics?
Currently, no hedge funds are holding shares in BCTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology